International outcomes in breast, cervical, and ovarian cancers highlight opportunities to improve health-care delivery for ...

A Lancet study finds that fewer than one in five women in poorer countries are diagnosed early with breast or cervical cancer ...

Daiichi and Merck saw the highest ORR—57.1%—in patients who received the top dose of R-DXd. Yet the drugmakers have opted to take the middle 5.6 mg/kg dose into the phase 3 part of the trial. The ORR ...

Day Fiancé’ star Liz Woods shares her emotional battle with stage 1 ovarian cancer, offering strength and awareness in the new season of ‘90 Day Diaries.’ ...

New Data Highlight Continued Potential of Radspherin to Prevent Disease Progression OSLO, Norway, Oct. 8, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing ...

The myths and misconceptions attached to ovarian cancer often lead to misdiagnosis and confusion. In an interview with HT Lifestyle, Dr Pushpinder Gulia, director, surgical oncology and robotic ...

The DUO-O trial showed significant improvement in progression-free survival with Imfinzi, Avastin, and Lynparza, but no ...

Preventing relapse of advanced ovarian cancer with PARP inhibitors is now an established strategy. As data from pivotal ...